<DOC>
	<DOCNO>NCT00625352</DOCNO>
	<brief_summary>Cares elderly patient advance non-small cell lung cancer ( NSCLC ) become one common clinical practice oncologist face . So , need seek adequate regimen . Gemcitabine well know one active third generation agent term efficacy tolerability . Gemcitabine alone recommend first line treatment elderly NSCLC patient , especially aspect tolerability . However , gemcitabine alone suggest suboptimal control disease . Therefore , plan make optimal regimen contain gemcitabine elderly patient .</brief_summary>
	<brief_title>Study Developing Optimal Gemcitabine Based Regimen Treat Elderly Patients With Advanced Non-Small Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm NonSmallCell Lung Cancer Stage IIIB/IV No prior chemotherapy Existence measurable disease . The measurable disease irradiate Life expectancy 3 month Age â‰¥ 70 year Performance status ( ECOG ) :1 2 Adequate bone marrow function ( Absolute neutrophil count &gt; 1500/mm^3 , Platelet count &gt; 100000/mm^3 , Hemoglobin &gt; 9gr/mm^3 ) Adequate liver ( Bilirubin &lt; 2 time upper limit normal SGOT/SGPT &lt; 3 time upper limit normal ) renal function ( creatinine &lt; 1.5mg/dl ) Informed consent Psychiatric illness social situation would preclude study compliance . Other concurrent uncontrolled illness . Other invasive malignancy within past 5 year except nonmelanoma skin cancer Currently/recently take warfarin , phenprocoumon phenytoin Hypersensitivity history drug</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Aged</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>UFT</keyword>
</DOC>